US Patent:
20030170740, Sep 11, 2003
Inventors:
Christos Hatzis - Cambridge MA, US
Nandan Padukone - Melrose MA, US
John Babish - Brooktondale NY, US
International Classification:
G01N033/53
G01N033/567
C07H021/04
A61K039/395
C07K014/72
A61K048/00
C07K016/30
US Classification:
435/007200, 435/069100, 435/320100, 435/325000, 424/143100, 514/044000, 530/350000, 536/023500
Abstract:
The invention relates to the gene encoding the mammalian E2IG3 and its product. More specifically, the invention relates to the diagnosis of aberrant E2IG3 gene or gene product expression, the identification, production, and use of compounds which modulate E2IG3 expression or the activity of the E2IG3 gene product including but not limited to nucleic acid encoding E2IG3 and homologues, analogues, and deletions thereof, as well as antisense, ribozyme, triplehelix, antibody, and polypeptide molecules as well as small inorganic molecules; and pharmaceutical formulations and routes of administration for such compounds.